Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Jun 11;9:8470. doi: 10.1038/s41598-019-44878-w

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2019

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Gene expression profile of Fgf8b and PPARy agonist treated white adipocytes. White adipocytes were treated with Fgf8b (125 ng/ml) and/or rosiglitazone (20 µM) during differentiation. (A,B) Transcript abundance of genes indicative for brown adipocytes, brite markers, adipogenesis, and FGF signalling (abbreviations below), n = 3–6. Fgf8b treatment leads to significantly different abundance of all transcripts analysed except Tbx1, Slc21a1 and Fgfrs 3 and 4 both in the absence and in the presence of rosiglitazone and except Fgf21 in the presence of rosiglitazone (Holm-Sidak multiple testing). (C) Representative Western Blot detecting terminal adipogenic differentiation markers HSL and perilipin and mitochondrial marker COX4. (D) Quantified, normalized band intensity of proteins detected in (C), n = 3, bars represent mean values ± SD. Stars indicate a significantly different abundance of this transcript as compared to the control. Ucp1, uncoupling protein 1; Cidea, cell death-inducing DNA fragmentation factor alpha-like effector A; Pgc1a, peroxisome proliferator-activated receptor gamma, coactivator 1 alpha; Cs, citrate synthase; Prdm16, PR domain containing 16; Tmem26, Transmembrane protein 26; Tbx1, T-box transcription factor 1; Cd137, cluster of differentiation 137; Hoxc9, homeobox C9; Shox2, Short stature homeobox 2; Slc27a1, Long-chain fatty acid transport protein 1; Pparg, peroxisome proliferator-activated receptor gamma; Fabp4, fatty acid binding protein 4; Hsl, hormone-sensitive lipase; Fasn, fatty Acid Synthase; Pref-1, preadipocyte secreted factor-1; Fgfr, fibroblast growth factor receptor; Klb, klotho beta; Fgf21, fibroblast growth factor 21; HSL, hormone sensitive lipase; PLIN, perilipin; COX4, cytochrome C oxidase subunit 4.